共 50 条
- [1] The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC Reply JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
- [3] Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors Cancer Immunology, Immunotherapy, 2021, 70 : 2559 - 2576